公开(公告)号：US20240189281A1

公开(公告)日：2024-06-13

申请号：US18481141

申请日：2023-10-04

申请人： Sabre Therapeutics LLC

发明人： John Howard Hutchinson ,  David Lonergan

IPC分类号： A61K31/4155 ,  A61K9/00 ,  A61K9/06 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K31/4439 ,  A61K45/06 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D493/10

CPC分类号： A61K31/4155 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/06 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K31/4439 ,  A61K45/06 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D493/10

摘要： Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.

公开(公告)号：US12005141B2

公开(公告)日：2024-06-11

申请号：US18339267

申请日：2023-06-22

申请人： LIQMEDS WORLDWIDE LIMITED

发明人： Jayanta Kumar Mandal ,  Malay Patel ,  Swati Nagar ,  Michael Paul DeHart

IPC分类号： A61K9/08 ,  A61K31/4418 ,  A61K47/10 ,  A61K47/26

CPC分类号： A61K9/08 ,  A61K31/4418 ,  A61K47/10 ,  A61K47/26

摘要： Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

公开(公告)号：US12005062B2

公开(公告)日：2024-06-11

申请号：US18365266

申请日：2023-08-04

申请人： LIQMEDS WORLDWIDE LIMITED

发明人： Jinal Pandya ,  Sandip P. Mehta ,  Manish Umrethia ,  Jayanta Kumar Mandal ,  Hiren Pansuriya

IPC分类号： A61K31/4985 ,  A61K9/08 ,  A61K31/519 ,  A61K47/10

CPC分类号： A61K31/519 ,  A61K9/08 ,  A61K31/4985 ,  A61K47/10

摘要： The present disclosure is directed to pharmaceutical compositions comprising sildenafil or a pharmaceutically acceptable salt thereof and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of sildenafil or a pharmaceutically acceptable salt thereof such as pulmonary arterial hypertension, erectile dysfunction, etc.

公开(公告)号：US20240181064A1

公开(公告)日：2024-06-06

申请号：US18233853

申请日：2023-08-14

申请人： Exela Pharma Sciences, LLC

发明人： Sreerama Murthy Mallipeddi ,  Jonathan E. Sterling ,  Phanesh B. Koneru

IPC分类号： A61K47/26 ,  A61K9/00 ,  A61K9/08 ,  A61K31/522 ,  A61K47/02 ,  A61K47/10

CPC分类号： A61K47/26 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/522 ,  A61K47/02 ,  A61K47/10

摘要： Gancyclovir formulations that are ready-to-use, substantially particulate free, and stable upon storage are disclosed. Methods of manufacture and administration of such compositions are also provided.

公开(公告)号：US20240180957A1

公开(公告)日：2024-06-06

申请号：US18533373

申请日：2023-12-08

申请人： Mandos LLC

发明人： Bernardus Nicolaas Machielse ,  Allan Darling

IPC分类号： A61K31/724 ,  A61K9/00 ,  A61K9/08

CPC分类号： A61K31/724 ,  A61K9/0019 ,  A61K9/0085 ,  A61K9/08

摘要： This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

公开(公告)号：US20240180826A1

公开(公告)日：2024-06-06

申请号：US18530529

申请日：2023-12-06

申请人： Marc Selner

发明人： Marc Selner

IPC分类号： A61K9/08 ,  A61K9/00 ,  A61K38/13 ,  A61K47/10 ,  A61K47/18 ,  A61K47/20 ,  A61K47/26 ,  A61K47/36

CPC分类号： A61K9/08 ,  A61K9/0048 ,  A61K38/13 ,  A61K47/10 ,  A61K47/183 ,  A61K47/20 ,  A61K47/26 ,  A61K47/36

摘要： This invention presents novel ophthalmic formulations featuring cyclosporine to address eye irritation linked to traditional dry eye treatments. The formulation incorporates pure cyclosporine A and achieves water solubility without the need for lipids or emulsifiers, enhancing bioactivity. Preferred embodiments include moisturizing agents and osmolarity adjusters to improve efficacy. The invention provides two formulation methods, both excluding fats and emulsifiers for water solubility.

公开(公告)号：US11998633B2

公开(公告)日：2024-06-04

申请号：US17289382

申请日：2019-10-16

申请人： Amorepacific Corporation

发明人： Wonkyung Cho ,  Kwanghyun Shin ,  Joonho Choi ,  Kiwha Lee ,  Jong Hwa Roh ,  Miyoung Park ,  Youngho Park ,  Eunsil Park ,  Jaehong Park ,  Byoung Young Woo ,  Min Soo Kim ,  Eun Sol Ha

IPC分类号： A61K9/08 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61K9/00

CPC分类号： A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61K9/0014

摘要： One aspect of the present disclosure relates to a sol-gel composition enabling reversible sol-gel transition and, more specifically, to a sol-gel composition of which the viscosity changes by external physical force so that reversible sol-gel transition is performed.

公开(公告)号：US20240173317A1

公开(公告)日：2024-05-30

申请号：US18382636

申请日：2023-10-23

申请人： MIRUM PHARMACEUTICALS, INC.

发明人： Thomas JAECKLIN

IPC分类号： A61K31/4995 ,  A61K9/00 ,  A61K9/08 ,  A61K31/07 ,  A61K31/355 ,  A61K31/593 ,  A61K47/10 ,  A61P1/16

CPC分类号： A61K31/4995 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/07 ,  A61K31/355 ,  A61K31/593 ,  A61K47/10 ,  A61P1/16

摘要： Provided herein are methods for treating cholestasis in a subject having liver disease. More specifically, the present invention relates to methods for treating Progressive Familial Intrahepatic Cholestasis (PFIC) in a subject where the method includes administering maralixibat to a subject in need thereof.

公开(公告)号：US20240173254A1

公开(公告)日：2024-05-30

申请号：US18551084

申请日：2022-03-18

申请人： ORION CORPORATION

发明人： Johanna KUJALA ,  Jenni LEHTISALO ,  Jukka SALMIA ,  Kai SINERVO

IPC分类号： A61K9/08 ,  A61K9/00 ,  A61K31/4178 ,  A61K47/12

CPC分类号： A61K9/08 ,  A61K9/0053 ,  A61K31/4178 ,  A61K47/12

摘要： The present disclosure relates to a pharmaceutical composition in the form of an orally deliverable liquid composition comprising tasipimidine, or a pharmaceutically acceptable salt thereof, as an active ingredient and to the use thereof in the treatment and prevention of a disorder, condition or disease where an alpha2A agonist is indicated to be useful, for example, for use as a sedative or analgesic agent, and for use in the treatment of anxiety or agitation. The composition is stable at the pH range from about 2.0 to about 5.0.

公开(公告)号：US11992488B2

公开(公告)日：2024-05-28

申请号：US16395547

申请日：2019-04-26

申请人： Eye Therapies, LLC

发明人： Gerald Horn

IPC分类号： A61K31/498 ,  A61K9/00 ,  A61K9/08 ,  A61K47/10 ,  A61K47/26 ,  A61K47/40 ,  A61P27/02

CPC分类号： A61K31/498 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/0073 ,  A61K9/08 ,  A61K47/10 ,  A61K47/26 ,  A61K47/40 ,  A61P27/02

摘要： The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH from about 4.0 to about 7.5.